BiotechnologyJ INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI ‘JIN-A02’ at the 2022 World Conference on Lung Cancer in Vienna, Austria (IASLC 2022 WCLC)

INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI ‘JIN-A02’ was presented on the 8th of August, at the 2022 IASLC World Conference on Lung Cancer held in Vienna, Austria, during the official session entitled “Overcoming Resistance to EGFR Inhibitors”.

Prof. Cho Byoung-chul, Director of the Lung Cancer Center at Yonsei Cancer Hospital, Korea, presented data which indicates that ‘JIN-A02’ targets NSCLC cancers harboring double or triple C797S mutations.

In-vitro and in-vivo data of ‘JIN-A02’ showed robust inhibitory activities against NSCLC cancer cell-lines harboring double and triple C797S mutations, with selectivity away from EGFR Wild Type, which is important for patient safety.

In addition, ‘JIN-A02’ also effectively reduced tumor volume in a dose-dependent manner, compared to Osimertinib, in mouse model harboring EGFR C797S triple mutation, showing high brain penetrance with efficacy. Prof. Cho ended his presentation by putting forth that JIN-A02 may be the Best-In-Class 4th generation EGFR-TKI against NSCLC.

PRNewswire

Leave a Reply

Your email address will not be published. Required fields are marked *